Humanigen Inc (HGENQ)

[Fezziwig2008]

Case Report- Presching to the Choir: “ HGEN - case report out yesterday: “Humanigen unveiled findings that lenzilumab- targets GM-CSF helped an elderly man w/history included type 2 DM, coronary artery disease -a coronary artery bypass graft, systolic heart failure, severe COPD, emphysema and sleep apnea. The 77yo tested positive for SARS-CoV-2 and was admitted to an ICU in March on respiratory isolation-Rxd w/ steroids, antibiotics for community-acquired pneumonia, & bronchodilators for possible COPD exacerbation, hydroxychloroquine plus zinc. He deteriorated for 12 wks with an increase in O2 demand from continuous low to high-flow, eventually bilevel positive airway pressure. He developed ARDS.

At week 13 after unsuccessful attempts at oxygen weaning, an emergency, single-use IND for lenzilumab was cleared by the FDA and administered to the patient. 7 days later, O2 need decreased from high to low-flow nasal cannula, and he was able to walk outside of his hospital room. 16d post treatment, he was discharged on home O2 - Bullish”